GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Apyx Medical Corp (NAS:APYX) » Definitions » Total Equity

APYX (Apyx Medical) Total Equity : $11.20 Mil (As of Sep. 2024)


View and export this data going back to 1994. Start your Free Trial

What is Apyx Medical Total Equity?

Apyx Medical's total equity for the quarter that ended in Sep. 2024 was $11.20 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Apyx Medical Total Equity Historical Data

The historical data trend for Apyx Medical's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apyx Medical Total Equity Chart

Apyx Medical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 71.26 63.86 54.01 37.79 26.92

Apyx Medical Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 33.59 26.92 20.46 14.92 11.20

Apyx Medical Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Apyx Medical's Total Equity for the fiscal year that ended in Dec. 2023 is calculated as

Total Equity=Total Assets(Q: Dec. 2023 )-Total Liabilities(Q: Dec. 2023 )
=79.24-52.318
=26.92

Apyx Medical's Total Equity for the quarter that ended in Sep. 2024 is calculated as

Total Equity=Total Assets(Q: Sep. 2024 )-Total Liabilities(Q: Sep. 2024 )
=60.721-49.524
=11.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apyx Medical Total Equity Related Terms

Thank you for viewing the detailed overview of Apyx Medical's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Apyx Medical Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Apyx Medical Corp (NAS:APYX) » Definitions » Total Equity
Comparable Companies
XTNT LUCD MODD CTSO IRME RPID NXL NVNO COCH OM ABT SYK BSX MDT XTER:SHL SZSE:300760 EW DXCM XAMS:PHIA ZBH
Traded in Other Exchanges
BOV:Germany BOV:Germany
Address
5115 Ulmerton Road, Clearwater, FL, USA, 33760
Website
https://apyxmedical.com
Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Advanced Energy and Original Equipment Manufacturing (OEM). Its Advanced Energy segment derives the majority of its revenue.
Executives
Todd Hornsby officer: Executive Vice President 14321 HAWTHORNE DR., CARMEL IN 46033
Goodwin Charles D. Ii director, officer: Chief Executive Officer 5115 ULMERTON ROAD, CLEARWATER FL 33760
Wendy Lauren Levine director 75 KENMARE STREET, APT. 2D, NEW YORK NY 10012
Minnie Baylor-henry director C/O SCPHARMACUETICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01803
Tara Semb officer: Chief Financial Officer 5516 RIVERSIDE HEIGHTS WAY, RICHMOND VA 23225
Craig A. Swandal director 5115 ULMERTON ROAD, CLEARWATER FL 33760
Michael Geraghty director 1342 CHERRY HILL ROAD, MENDOTA HEIGHTS MN 55118
Lawrence Waldman director 5115 ULMERTON RD., CLEARWATER FL 33770
John C. Andres director 86 CAPRI LANE, CHATHAM MA 02633
Jay D. Ewers officer: Chief Financial Officer 4 MANHATTANVILLE ROAD, SUITE 106, PURCHASE NY 10577
J Robert Saron director, officer: President
Robert Gershon director, officer: Chief Executive Officer 5115 ULMERTON ROAD, CLEARWATER FL 33760
Mccarthy John J. Iii officer: Chief CommercializationOfficer 23 RINALDO ROAD, NORTHPORT NY 11768
Scott Richard Davidson director C/O GREAT POINT PARTNERS, LLC, 165 MASON STREET, GREENWICH CT 06830
Moshe Citronowicz officer: Vice President of Operations